BillebeauGVodovarNSadouneM. Effects of a cardiac rehabilitation program on plasma cardiac biomarkers in patients with chronic heart failure. Eur J Prev Cardiol2017; 24: 1127–1135.
2.
Tóth-ZsambokiEHorváthZHajtmanL. Cardiac rehabilitation program as a non-pharmacological platelet inhibitory tool in acute coronary syndrome survivors. Eur J Prev Cardiol2017; 24: 1148–1156.
3.
KormiINieminenMTHavulinnaAS. Matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 predict incident cardiovascular disease events and all-cause mortality in a population-based cohort. Eur J Prev Cardiol2017; 24: 1136–1144.
4.
UelandTLaugsandLEVattenL. Extracellular matrix markers and risk of myocardial infarction: The HUNT Study in Norway. Eur J Prev Cardiol2017; 24: 1161–1167.
5.
HuangWReschSOliveiraRKF. Invasive cardiopulmonary exercise testing in the evaluation of unexplained dyspnea: Insights from a multidisciplinary dyspnea center. Eur J Prev Cardiol2017; 24: 1190–1199.
6.
MadaniNHIsmail-BeigiFKhamsehME. Predictive and explanatory factors of cardiovascular disease in people with adequately controlled type 2 diabetes. Eur J Prev Cardiol2017; 24: 1181–1189.
7.
EllisKLPangJSchultzC. New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials. Eur J Prev Cardiol2017; 24: 1200–1205.
8.
NorrishGCantaruttiNPissaridouE. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. Eur J Prev Cardiol2017; 24: 1220–1230.
9.
MourtzinisGSchilerLKahanT. Antihypertensive control and new-onset atrial fibrillation. Results from the Swedish Primary Care Cardiovascular Database (SPCCD). Eur J Prev Cardiol2017; 24: 1206–1211.
10.
WagnerMWannerCKotsevaK. on behalf of the EUROASPIRE IV investigators. Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: Insights from the EUROASPIRE IV Survey of the European Society of Cardiology. Eur J Prev Cardiol2017; 24: 1168–1180.
11.
O’NealWTSandesaraPBSamman-TahhanA. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol2017; 24: 1212–1219.
